TMEM106A and hepatocellular carcinoma: Herein, we observed a decreased expression of TMEM106A in highly metastatic hepatoma cells, which was related to TMEM106A promoter methylation and was reversed by treatment with a demethylating agent, 5-Aza-2′-deoxycytidine.